Tesla Cybertruck and the new Model 3 have both fallen short of the top marks in IIHS’ latest round of crash tests. Over the years, Tesla has consistently earned top safety ratings from various ...

Baidu just dropped something pretty interesting in the AI scene. After their recent launch of Ernie X1.1 deep thinking model, they’ve now released PP-OCRv5, a new optical character recognition model ...

As summer comes to an end, COVID-19 cases are on the rise again in California. While respiratory viruses usually peak in the winter, the novel coronavirus can also surge in the warmer months.

“These tests need to benefit the patients, not Harvard, Dana-Farber, Karolinska Institute and Mayo Clinic, they should benefit the patient,” MMAS Research Solutions Architect Steve Trubow said. A ...

A simple brainwave test developed at the University of Bath has been shown to detect signs of memory impairment linked to Alzheimer's disease years before clinical diagnosis is typically possible.

Researchers at the Johns Hopkins University School of Medicine and the National Institutes of Health, in collaboration with the UK Biobank and the University of Turin, Italy, have identified a ...

The electric SUV market is more competitive than ever. Just a few years ago, the Tesla Model Y stood alone in the compact EV segment, yet today it’s joined by eight other nameplates vying for ...

(RTTNews) - The first FDA-cleared blood test that aids in the diagnosis of Alzheimer's disease has been launched by Labcorp (LH), a global life sciences and healthcare company. The test, named ...

Wendy Williams’ complex guardianship situation continues following the completion of comprehensive medical testing that reaffirmed her neurological condition. The former television personality ...

Please provide your email address to receive an email when new articles are posted on . It is estimated that at least 12 million people in the United States are affected by diagnostic errors each year ...

The FDA approved the Oncomine Dx Target Test for identifying HER2-mutant NSCLC patients eligible for Hernexeos, an oral tyrosine kinase inhibitor. Hernexeos offers a new treatment option for ...